AR124090A1 - Moduladores del regulador de la conductancia transmembrana de la fibrosis quística - Google Patents
Moduladores del regulador de la conductancia transmembrana de la fibrosis quísticaInfo
- Publication number
- AR124090A1 AR124090A1 ARP210103184A ARP210103184A AR124090A1 AR 124090 A1 AR124090 A1 AR 124090A1 AR P210103184 A ARP210103184 A AR P210103184A AR P210103184 A ARP210103184 A AR P210103184A AR 124090 A1 AR124090 A1 AR 124090A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- optionally substituted
- alkyl
- cycloalkyl
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115552P | 2020-11-18 | 2020-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124090A1 true AR124090A1 (es) | 2023-02-15 |
Family
ID=79602287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103184A AR124090A1 (es) | 2020-11-18 | 2021-11-18 | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP4247817A1 (enExample) |
| JP (1) | JP2023549547A (enExample) |
| KR (1) | KR20230123522A (enExample) |
| CN (1) | CN116670140A (enExample) |
| AR (1) | AR124090A1 (enExample) |
| AU (1) | AU2021383176A1 (enExample) |
| CA (1) | CA3201793A1 (enExample) |
| CL (1) | CL2023001398A1 (enExample) |
| CO (1) | CO2023007896A2 (enExample) |
| CR (1) | CR20230260A (enExample) |
| DO (1) | DOP2023000099A (enExample) |
| EC (1) | ECSP23045439A (enExample) |
| GE (1) | GEAP202316271A (enExample) |
| IL (1) | IL302873A (enExample) |
| JO (1) | JOP20230105A1 (enExample) |
| MX (1) | MX2023005721A (enExample) |
| PE (1) | PE20231380A1 (enExample) |
| WO (1) | WO2022109573A1 (enExample) |
| ZA (1) | ZA202305296B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL314449A (en) * | 2022-02-03 | 2024-09-01 | Vertex Pharma | Methods of treatment for cystic fibrosis |
| WO2023154291A1 (en) * | 2022-02-08 | 2023-08-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4525858A1 (en) * | 2022-05-16 | 2025-03-26 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CA3253977A1 (en) | 2022-05-16 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | SOLID FORMS OF MACROCYCLIC COMPOUNDS AS CFTR MODULATORS AND THEIR PREPARATION |
| WO2024054851A1 (en) * | 2022-09-07 | 2024-03-14 | Sionna Therapeutics | Macrocyclic compounds, compositions and methods of using thereof |
| TW202421102A (zh) * | 2022-09-15 | 2024-06-01 | 瑞士商愛杜西亞製藥有限公司 | 巨環cftr調節劑與cftr校正子及/或cftr增效劑之組合 |
| KR20250084132A (ko) | 2022-09-15 | 2025-06-10 | 이도르시아 파마슈티컬스 리미티드 | 마크로시클릭 cftr 조절제 |
| CA3267791A1 (en) | 2022-09-15 | 2024-03-21 | Idorsia Pharmaceuticals Ltd | CRYSTALLINE FORM OF (3S,7S,10R,13R)-13-BENZYL-20-FLUORO-7-ISOBUTYL-N-(2-(3-METHOXY-1,2,4-OXADIAZOL-5-YL)ETHYL)-6,9-DIMETHYL-1,5,8,11-TETRAOXO-10-(2,2,2-TRIFLUOROETHYL)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-TETRADECAHYDRO-[1]OXA[4,7,10,14]TETRAAZACYCLOHEPTADECINO [16,17-F]QUINOLINE-3-CARBOXAMIDE |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025076240A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013038386A1 (en) * | 2011-09-16 | 2013-03-21 | Novartis Ag | Heterocyclic compounds for the treatment of cystic fibrosis |
| SI3519401T1 (sl) * | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
| CN110267948B (zh) * | 2016-12-09 | 2023-12-08 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控剂的调节剂、药物组合物、治疗方法和制备所述调节剂的方法 |
| TWI810243B (zh) * | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
| AU2019222758B2 (en) * | 2018-02-15 | 2022-07-07 | Vertex Pharmaceuticals Incorporated | Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cystic fibrosis, and process for making them |
| CN109134431B (zh) * | 2018-10-10 | 2021-06-04 | 成都理工大学 | 作为囊性纤维化跨膜传导调节因子抑制剂的氨基咪唑偶联吡啶酮衍生物 |
| TWI848092B (zh) * | 2019-04-03 | 2024-07-11 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白調節劑 |
-
2021
- 2021-11-17 KR KR1020237020002A patent/KR20230123522A/ko active Pending
- 2021-11-17 CA CA3201793A patent/CA3201793A1/en active Pending
- 2021-11-17 WO PCT/US2021/072475 patent/WO2022109573A1/en not_active Ceased
- 2021-11-17 AU AU2021383176A patent/AU2021383176A1/en active Pending
- 2021-11-17 EP EP21843853.9A patent/EP4247817A1/en active Pending
- 2021-11-17 GE GEAP202316271A patent/GEAP202316271A/en unknown
- 2021-11-17 PE PE2023001653A patent/PE20231380A1/es unknown
- 2021-11-17 MX MX2023005721A patent/MX2023005721A/es unknown
- 2021-11-17 CN CN202180090910.1A patent/CN116670140A/zh active Pending
- 2021-11-17 CR CR20230260A patent/CR20230260A/es unknown
- 2021-11-17 JP JP2023529022A patent/JP2023549547A/ja active Pending
- 2021-11-17 IL IL302873A patent/IL302873A/en unknown
- 2021-11-18 AR ARP210103184A patent/AR124090A1/es unknown
-
2023
- 2023-05-11 JO JOJO/P/2023/0105A patent/JOP20230105A1/ar unknown
- 2023-05-15 ZA ZA2023/05296A patent/ZA202305296B/en unknown
- 2023-05-16 CL CL2023001398A patent/CL2023001398A1/es unknown
- 2023-05-17 DO DO2023000099A patent/DOP2023000099A/es unknown
- 2023-06-16 EC ECSENADI202345439A patent/ECSP23045439A/es unknown
- 2023-06-16 CO CONC2023/0007896A patent/CO2023007896A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202316271A (en) | 2023-10-25 |
| JP2023549547A (ja) | 2023-11-27 |
| JOP20230105A1 (ar) | 2023-05-11 |
| KR20230123522A (ko) | 2023-08-23 |
| EP4247817A1 (en) | 2023-09-27 |
| CO2023007896A2 (es) | 2023-09-18 |
| CA3201793A1 (en) | 2022-05-27 |
| CN116670140A (zh) | 2023-08-29 |
| CR20230260A (es) | 2023-10-05 |
| AU2021383176A1 (en) | 2023-06-22 |
| IL302873A (en) | 2023-07-01 |
| CL2023001398A1 (es) | 2023-11-24 |
| WO2022109573A1 (en) | 2022-05-27 |
| DOP2023000099A (es) | 2023-08-15 |
| PE20231380A1 (es) | 2023-09-07 |
| MX2023005721A (es) | 2023-07-25 |
| ZA202305296B (en) | 2025-09-25 |
| ECSP23045439A (es) | 2023-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR124090A1 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
| AR123183A1 (es) | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística | |
| AR114254A1 (es) | Moduladores del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso de preparación de los moduladores | |
| AR126073A1 (es) | N-(hidroxialquil(hetero)aril)tetrahidrofuran carboxamidas como moduladores de canales de sodio | |
| AR109560A1 (es) | Compuestos moduladores de receptores tipo toll | |
| AR121959A1 (es) | Imidazopiridazinas como moduladores de il-17 | |
| AR117200A1 (es) | Derivados de tiazol microbiocidas | |
| AR054035A1 (es) | Derivados benzodioxano y benzodioxolano y uso de los mismos | |
| EA202090658A1 (ru) | Ингибиторы кэп-зависимой эндонуклеазы | |
| YU48912B (sh) | Novi sulfonamidski antagonisti receptora fibrinogena | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR073993A1 (es) | Compuesto de pirazolilaminopiridina, composicion farmaceuticamente aceptable que lo comprende y su uso para preparar un medicamento util para tratar el cancer | |
| BR9307595A (pt) | Composto, processo para sua preparação, composição herbicida, e, processo para danificar severamente ou exterminar plantas indesejáveis | |
| AR035795A1 (es) | Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de la enzima endopeptidasa neutra, uso de los mismos, procedimientos e intermediarios para su preparación y composiciones que contienen dichos inhibidores | |
| CY1124528T1 (el) | Ν-υποκατεστημενα παραγωγα ινδολης | |
| BR112022003152A2 (pt) | Compostos farmacêuticos | |
| AR005338A1 (es) | Derivados acetidinalquilicos de heterociclos con nitrogeno n-sustituido o sales farmaceuticamente aceptables de los mismos, un procedimiento paraprepararlos, composiciones farmaceuticas que los comprenden, uso de dichos derivados, sales y composiciones, y compuestos utilizables como intermedios | |
| AR125866A1 (es) | Inhibidores de la interacción de menina-mll | |
| AR117122A1 (es) | INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA | |
| AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
| AR062405A1 (es) | Derivados de isoindol | |
| YU46716B (sh) | Pentadienamidi | |
| PY2228191A (es) | Nuevos derivados de heteroaril aminopropanol | |
| AR088202A1 (es) | Inhibidores de la actividad de proteina tirosina quinasa | |
| AR093281A1 (es) | Benzotiazoles ligados a amida, urea o sulfonamida como inhibidores de la lipasa endotelial |